Statistics for A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Total visits
| views | |
|---|---|
| A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response. | 38 |
Total visits per month
| views | |
|---|---|
| marzo 2024 | 0 |
| abril 2024 | 4 |
| mayo 2024 | 5 |
| junio 2024 | 0 |
| julio 2024 | 0 |
| agosto 2024 | 0 |
| septiembre 2024 | 0 |
File Visits
| views | |
|---|---|
| Paper Oncoimmunology.pdf | 56 |